BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

...removing two brakes from the immune system may not work for all cancers, and said Corvas...
BioCentury | Jan 9, 2012
Finance

Trending up

...December. The biotech has rights to a patent covering Victrelis through its 2003 acquisition of Corvas International Inc....
BioCentury | Dec 12, 2011
Company News

Dendreon, CPP Investment Board deal

...Dendreon has rights to U.S. Patent No. 7,012,066 covering Victrelis through its 2003 acquisition of Corvas International Inc....
BioCentury | Dec 12, 2011
Finance

Highlights of weekly biotech stock moves

...Inc. (NYSE:MRK). Dendreon has rights to a patent covering Victrelis through its 2003 acquisition of Corvas International Inc....
BioCentury | Apr 10, 2006
Strategy

Home run in extra innings

...The first, a 1995 deal with Corvas International Inc. , didn't pan out. In 2002, PFE and Corvas...
...factor (NIF) to treat acute stroke, did not support the start of Phase III testing. Corvas...
BioCentury | Feb 17, 2006
Company News

Conforma names Crawford CFO

...Calif.) hired John Crawford, a consultant, as CFO. Crawford was a founder of cardiovascular company Corvas...
BioCentury | Feb 9, 2004
Company News

Dendreon, Nuvelo deal

...deal will let it focus on oncology, gained the compounds through its 2003 acquisition of Corvas International Inc....
BioCentury | Feb 9, 2004
Strategy

Nuvelo's bargain basement pipeline

...company had no intention of developing the cardiovascular compounds, obtained through its 2003 acquisition of Corvas International Inc....
...not really a Phase II compound. He characterized it as "more like Phase I" because Corvas'...
...safety. rNAPc2 also had completed a Phase II study in deep vein thrombosis (DVT), but Corvas...
BioCentury | Feb 5, 2004
Company News

Nuvelo licenses anticoagulant from Dendreon

...deal will let it focus on oncology, gained the compounds through its 2003 acquisition of Corvas...
BioCentury | Jan 5, 2004
Finance

Restructuring watch

...12/17/03 Dendreon (DNDN) 15% to 165 Closing San Diego opertations gained through the acquisition of Corvas...
Items per page:
1 - 10 of 161
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

...removing two brakes from the immune system may not work for all cancers, and said Corvas...
BioCentury | Jan 9, 2012
Finance

Trending up

...December. The biotech has rights to a patent covering Victrelis through its 2003 acquisition of Corvas International Inc....
BioCentury | Dec 12, 2011
Company News

Dendreon, CPP Investment Board deal

...Dendreon has rights to U.S. Patent No. 7,012,066 covering Victrelis through its 2003 acquisition of Corvas International Inc....
BioCentury | Dec 12, 2011
Finance

Highlights of weekly biotech stock moves

...Inc. (NYSE:MRK). Dendreon has rights to a patent covering Victrelis through its 2003 acquisition of Corvas International Inc....
BioCentury | Apr 10, 2006
Strategy

Home run in extra innings

...The first, a 1995 deal with Corvas International Inc. , didn't pan out. In 2002, PFE and Corvas...
...factor (NIF) to treat acute stroke, did not support the start of Phase III testing. Corvas...
BioCentury | Feb 17, 2006
Company News

Conforma names Crawford CFO

...Calif.) hired John Crawford, a consultant, as CFO. Crawford was a founder of cardiovascular company Corvas...
BioCentury | Feb 9, 2004
Company News

Dendreon, Nuvelo deal

...deal will let it focus on oncology, gained the compounds through its 2003 acquisition of Corvas International Inc....
BioCentury | Feb 9, 2004
Strategy

Nuvelo's bargain basement pipeline

...company had no intention of developing the cardiovascular compounds, obtained through its 2003 acquisition of Corvas International Inc....
...not really a Phase II compound. He characterized it as "more like Phase I" because Corvas'...
...safety. rNAPc2 also had completed a Phase II study in deep vein thrombosis (DVT), but Corvas...
BioCentury | Feb 5, 2004
Company News

Nuvelo licenses anticoagulant from Dendreon

...deal will let it focus on oncology, gained the compounds through its 2003 acquisition of Corvas...
BioCentury | Jan 5, 2004
Finance

Restructuring watch

...12/17/03 Dendreon (DNDN) 15% to 165 Closing San Diego opertations gained through the acquisition of Corvas...
Items per page:
1 - 10 of 161